Blue Earth Therapeutics
Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company developing PSMA-targeted radiohybrid radioligand therapies (177Lu-rhPSMA-10.1 and 225Ac-rhPSMA-10.1) for metastatic castrate-resistant prostate cancer, serving oncologists and nuclear medicine specialists.
- Company typePrivate
- Founded2021
- HeadquartersOxford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Blue Earth Therapeutics does
Blue Earth Therapeutics Limited is a clinical-stage radiopharmaceutical company headquartered at The Oxford Science Park, Magdalen Centre, Oxford, UK. Founded in 2021 as a subsidiary of Bracco Imaging and partly spun out following a $76.5 million Series A financing in October 2024, the company develops targeted radioligand therapies (RLTs) for prostate cancer, with its primary indication being metastatic castrate-resistant prostate cancer (mCRPC).
The company's pipeline is anchored by its proprietary radiohybrid PSMA (rhPSMA-10.1) platform, a PSMA-targeting molecule with an optimized molecular design incorporating a carboxylic acid side chain and a SiFa group, intended to increase tumor affinity, optimize albumin binding, modulate overall charge, and improve internalization and retention. The platform is being advanced through two programs: 177Lu-rhPSMA-10.1 Injection, a lutetium-177 (beta-emitting) agent currently in Phase 2 clinical trials following FDA IND clearance (April 2022) and UK MHRA Innovation Passport designation (November 2022); and 225Ac-rhPSMA-10.1, an actinium-225 (alpha-emitting) agent in preclinical development for targeted alpha therapy. Blue Earth Therapeutics holds exclusive worldwide rights to the rhPSMA targeted technology for therapeutic use.
As a pre-revenue clinical-stage company, Blue Earth Therapeutics generates no product revenue and is funded through venture capital and strategic financing. Its go-to-market motion targets healthcare professionals, oncologists, and nuclear medicine specialists at large healthcare institutions and academic medical centers, with clinical trial sites serving as the current distribution channel. Manufacturing and isotope supply are outsourced through strategic partners, including SHINE Technologies (Lutetium-177 supply) and Seibersdorf Labor GmbH (Actinium-225 manufacturing), with a clinical research collaboration in place with University College London for alpha-labelled RLT development. The company operates with a UK/US-based team and a leadership group that includes repeat radiopharmaceutical founders from the prior Blue Earth Diagnostics business acquired by Bracco Imaging in 2019.
Blue Earth Therapeutics firmographics
Firmographics- Name
- Blue Earth Therapeutics
- Legal name
- Blue Earth Therapeutics Limited
- Website
- https://blueearththerapeutics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company developing PSMA-targeted radiohybrid radioligand therapies (177Lu-rhPSMA-10.1 and 225Ac-rhPSMA-10.1) for metastatic castrate-resistant prostate cancer, serving oncologists and nuclear medicine specialists.
- Ownership category
- akta.pro rank
Blue Earth Therapeutics industry classification
Industry- Product category
- Radiopharmaceutical Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Radiation Oncology (HLAKAFAC), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)
Keywords
Where Blue Earth Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Blue Earth Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Radiopharmaceutical therapy development and commercialization: Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company developing targeted radiopharmaceutical therapies. The company generates revenue through the development and eventual commercialization of its PSMA-targeted radiohybrid radiopharmaceutical pipeline, initially focused on prostate cancer. As a pre-revenue clinical-stage company, the company is funded through venture capital and strategic financing.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Blue Earth Therapeutics product offering
Product offeringCore offering
Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company developing next-generation PSMA-targeted radiohybrid radioligand therapies for the treatment of prostate cancer. Its pipeline includes 177Lu-rhPSMA-10.1 Injection (a beta-emitting Lutetium-177 therapy currently in Phase 2 trials for metastatic castrate-resistant prostate cancer) and 225Ac-rhPSMA-10.1 (an alpha-emitting Actinium-225 therapy in preclinical development). The proprietary radiohybrid design aims to deliver higher tumor radiation doses while sparing healthy tissue.
Product overview
Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company developing a pipeline of PSMA-targeted radiohybrid radioligand therapies for prostate cancer. The company has two lead product candidates: 177Lu-rhPSMA-10.1 Injection (a lutetium-177 beta emitter currently in Phase 2 clinical trials) and 225Ac-rhPSMA-10.1 (an actinium-225 alpha emitter in preclinical development). Both products utilize the proprietary radiohybrid PSMA-targeting molecule designed to optimize biodistribution and clearance for improved therapeutic index.
Differentiator
Problem solved
Functional benefit
Products and services
- 177Lu-rhPSMA-10.1 Injection A Lutetium-177 labeled PSMA-targeted radiohybrid therapeutic injection for treatment of metastatic castrate-resistant prostate cancer (mCRPC); uses beta radiation to deliver targeted dose to prostate cancer cells expressing PSMA. Currently in Phase 2 clinical trials.
- 225Ac-rhPSMA-10.1 An Actinium-225 labeled PSMA-targeted radiohybrid therapeutic using alpha radiation for potential targeted alpha therapy of prostate cancer; alpha radiation causes double-strand DNA breaks across a shorter range for concentrated tumor cell damage. Currently in preclinical development.
Quantifiable outcome
- Phase 2 clinical trial initiated in May 2025 evaluating Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate-resistant prostate cancer.
- +2 more outcomes
Companies that use Blue Earth Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Blue Earth Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Blue Earth Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Seibersdorf Labor GmbHcoreBlue Earth Therapeutics expanded its partnership with Seibersdorf Labor GmbH to include the manufacture of therapeutic radiopharmaceutical 225Ac-rhPSMA-10.1. Seibersdorf Labor GmbH serves as a manufacturing partner for the company's alpha-emitting actinium-based therapeutic radiopharmaceutical.
- University College London (UCL)coreBlue Earth Therapeutics entered into a clinical research collaboration with UCL to develop an innovative alpha-labelled radioligand therapy (RLT) for prostate cancer. This collaboration focuses on advancing alpha-emitting radiopharmaceutical research in partnership with a leading academic institution.
- SHINE TechnologiescoreSHINE Technologies collaborated with Blue Earth Therapeutics as part of the Lu-177 industry partnerships, with SHINE providing Lutetium-177 production capabilities for targeted cancer treatments. This partnership supports the manufacturing and supply of radioisotopes for Blue Earth Therapeutics' radioligand therapy development.
- Bracco ImagingcoreBlue Earth Therapeutics was founded in 2021 as a subsidiary of Bracco Imaging and was subsequently spun out with Series A financing in 2024. Bracco Imaging is the parent company providing strategic oversight and operational support, with Fabio Tedoldi (Director of R&D of Global Business Unit Imaging at Bracco) serving on the Blue Earth Therapeutics Board of Directors.
Scale indicators2 records
Recent moves7 records
Expansion highlights6 records
Blue Earth Therapeutics competitors and assessment
Company assessmentOthers
- Bracco Imaging: Bracco Imaging is the strategic parent of Blue Earth Therapeutics and the owner of sibling Blue Earth Diagnostics. It is an ecosystem participant rather than a competitor, providing capital, board oversight, and a theranostic platform via the rhPSMA diagnostic franchise.
Emerging players
- Actinium Pharmaceuticals: Actinium Pharmaceuticals is a clinical-stage company developing antibody-directed radiation conjugates and targeted alpha therapies. It overlaps with Blue Earth Therapeutics' longer-term ambition around alpha-emitter oncology, though it uses a different targeting modality.
Direct peers
- Telix Pharmaceuticals: Telix commercializes Illuccix (PSMA-11 imaging) and is developing a pipeline of PSMA-targeted therapeutics. It overlaps directly with Blue Earth Therapeutics' theranostic strategy across imaging diagnostics and radioligand therapy.
- Lantheus Holdings: Lantheus is developing PNT2002, a PSMA-targeted radioligand therapy acquired via Point Biopharma, and markets the PSMA diagnostic agent Pylarify. It competes with Blue Earth Therapeutics in both imaging and therapy across the PSMA value chain.
- Bayer: Bayer is advancing PSMA-targeted radioligand therapy programs (notably through its alliance on 177Lu-PSMA-617–derived agents and Xofigo heritage in alpha-emitter oncology), making it a direct strategic competitor in PSMA RLT.
- Eli Lilly (Point Biopharma): Lilly acquired Point Biopharma, which had a clinical-stage PSMA-targeted radioligand therapy (PNT2002). Lilly is now a vertically integrated competitor with both diagnostic (POINT Biologics legacy) and therapeutic PSMA assets.
- AstraZeneca (Fusion Pharmaceuticals): AstraZeneca acquired Fusion Pharmaceuticals to gain targeted alpha therapy capability, including actinium-225 based PSMA-targeted candidates. It is the most directly comparable strategic acquirer of a clinical-stage targeted-radiopharma platform to Blue Earth Therapeutics.
- Novartis: Novartis commercializes Pluvicto (177Lu-PSMA-617), the first approved PSMA-targeted radioligand therapy for mCRPC. It is the most direct competitor to Blue Earth Therapeutics' lead 177Lu-rhPSMA-10.1 program and defines the efficacy/safety benchmark the company must beat.
Broad incumbents
- Curium: Curium is one of the world's largest nuclear medicine companies, manufacturing and distributing diagnostic and therapeutic radiopharmaceuticals globally. It is a broad incumbent against whom Blue Earth Therapeutics will compete for nuclear medicine channel access.
- ITM Isotope Technologies Munich: ITM is a specialized radiopharmaceutical company producing medical radioisotopes (including Lu-177) and developing targeted radioligand therapies. It competes more broadly across the radiopharma stack rather than in a single PSMA asset.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Blue Earth Therapeutics social profiles
Digital presenceBlue Earth Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Blue Earth Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Blue Earth Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Blue Earth Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Blue Earth Therapeutics
What does Blue Earth Therapeutics do?
Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company developing next-generation PSMA-targeted radiohybrid radioligand therapies for the treatment of prostate cancer. Its pipeline includes 177Lu-rhPSMA-10.1 Injection (a beta-emitting Lutetium-177 therapy currently in Phase 2 trials for metastatic castrate-resistant prostate cancer) and 225Ac-rhPSMA-10.1 (an alpha-emitting Actinium-225 therapy in preclinical development). The proprietary radiohybrid design aims to deliver higher tumor radiation doses while sparing healthy tissue.
Is Blue Earth Therapeutics a public or private company?
Blue Earth Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Blue Earth Therapeutics founded?
Blue Earth Therapeutics was founded in 2021. It employs 11 to 50 people.
Where is Blue Earth Therapeutics based?
Blue Earth Therapeutics is headquartered in Oxford, United Kingdom, in the Europe region.
How does Blue Earth Therapeutics make money?
One revenue line is on record: radiopharmaceutical therapy development and commercialization.
Who are Blue Earth Therapeutics's main competitors?
Bracco Imaging is listed as an others. Actinium Pharmaceuticals is listed as an emerging player. Direct peers are Telix Pharmaceuticals, Lantheus Holdings, Bayer, Eli Lilly (Point Biopharma), AstraZeneca (Fusion Pharmaceuticals) and Novartis. Broad incumbents are Curium and ITM Isotope Technologies Munich.
Does Blue Earth Therapeutics have an API?
No public API is recorded for Blue Earth Therapeutics.
What industry is Blue Earth Therapeutics in?
Blue Earth Therapeutics's product category is Radiopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 541714 and its SIC code is 2833.